This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Axovant's Gene Therapy Gets Rare Pediatric Disease Status
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.
Do Options Traders Know Something About Axovant (AXGT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.
Axovant (AXGT) Catches Eye: Stock Jumps 12%
by Zacks Equity Research
Axovant (AXGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Why Axovant Gene Therapies (AXGT) Stock Might be a Great Pick
by Zacks Equity Research
Axovant Gene Therapies (AXGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B
by Zacks Equity Research
Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.
Axovant (AXGT) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.
Top Ranked Momentum Stocks to Buy for May 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 5th
All You Need to Know About Axovant (AXGT) Rating Upgrade to Buy
by Zacks Equity Research
Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Axovant (AXGT) a New Buy Stock
by Zacks Equity Research
Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag
by Zacks Equity Research
The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.
Axovant Gene Therapies Enters Oversold Territory
by Zacks Equity Research
Axovant Gene Therapies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Axovant (AXGT) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Axovant (AXGT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Axovant (AXGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Axovant (AXGT) closed at $6.61, marking a +0.46% move from the previous day.
Axovant (AXGT) Stock Moves -1.31%: What You Should Know
by Zacks Equity Research
Axovant (AXGT) closed at $7.53 in the latest trading session, marking a -1.31% move from the prior day.
Axovant (AXGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Axovant (AXGT) closed at $7.69 in the latest trading session, marking a +0.92% move from the prior day.
Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.
Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates
by Zacks Equity Research
Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.
Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.
Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss
by Zacks Equity Research
Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.
IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus
by Zacks Equity Research
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.
Axovant (AXGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Axovant (AXGT) closed at $6.67 in the latest trading session, marking a +1.52% move from the prior day.